Verzenio

Generic name:abemaciclib [ a-BEM-a-SYE-klib ]
Drug class:CDK 4/6 inhibitors

Medically reviewed by Judith Stewart, BPharm. Last updated on May 12, 2022.

What is Verzenio?

Verzenio is a prescription medicine used to treat certain patients with HR-positive, HER2-negative breast cancer.

Verzenio is a targeted treatment known as a CDK4/6 inhibitor. It works inside the cell to block CDK4/6 activity and help stop the growth of cancer cells.

What is Verzenio used for?

Verzenio is used:

• in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) to treat adults with hormone receptor (HR)­ positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer with a high risk of coming back as determined by your healthcare provider.
• in combination with an aromatase inhibitor as the first endocrine-based therapy to treat women who have gone through menopause (postmenopausal), and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has worsened or that has spread to other parts of the body (metastatic).
• in combination with fulvestrant to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has worsened or spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy.
• alone to treat adults with HR-positive, HER2-negative breast cancer that has worsened or that has spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy and prior chemotherapy.

When Verzenio is used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor, also read the Patient Information for the prescribed product. Ask your healthcare pro...